A Randomised, Double-blind, Parallel-group, Placebo Controlled Study of Esomeprazole i.v. (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour) Administered for 72 Hours to Assess Prevention of Rebleeding in Subjects That Have Undergone Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer - the PUB Study.

Trial Profile

A Randomised, Double-blind, Parallel-group, Placebo Controlled Study of Esomeprazole i.v. (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour) Administered for 72 Hours to Assess Prevention of Rebleeding in Subjects That Have Undergone Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer - the PUB Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jan 2017

At a glance

  • Drugs Esomeprazole; Esomeprazole
  • Indications Bleeding ulcer; Gastrointestinal haemorrhage
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PUB
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Jan 2017 Results of post hoc multivariable analyses published in the American Journal of Gastroenterology.
    • 30 May 2009 Results presented at DDW 2009.
    • 24 Apr 2009 Results have been reported in the Annals of Internal Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top